Detection of serum and intrahepatic KL-6 in anti-HCV positive patients with hepatocellular carcinoma

Moriyama, Mitsuhiko; Matsumura, Hiroshi; Watanabe, Azuma; Nakamura, Hitomi; Arakawa, Yasuo; Oshiro, Shuh; Aoki, Hiroshi; Shimizu, Toshihiro; Yanagimoto, Hiroaki; Kushima, Miki; Shioda, Atsuo; Tanaka, Naohide; Arakawa, Yasuyuki

doi:10.1016/j.hepres.2004.04.007

Cited by 14 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results indicate that serum KL-6 is a useful marker for HCC in patients with chronic liver disease and HCV. This result is in agreement with previous data reported Moriyama et al [28] .…”

Section: Discussionsupporting

confidence: 94%

See 1 more Smart Citation

Usefulness of the Serum KL-6 Assay in Patients with Hepatitis C Virus

Arase

Ikeda²,

Suzuki³

et al. 2005

Intervirology

View full text Add to dashboard Cite

Objective: The aim of this study is to evaluate the serum level of KL-6 in hepatitis C virus (HCV)-positive patients with chronic liver disease. Methods and Results: Subjects consisted of 502 HCV-positive patients. The serum samples of these patients stored at –80°C were measured by enzyme-linked immunosorbent assay for KL-6 at the same time. The cutoff point of the serum KL-6 level was defined as 500 U/ml. The serum KL-6 level of the 502 patients ranged between 71 and 2,295 (median, 223) U/ml. Thirty-two of the 502 (6.4%) patients showed an elevated KL-6 level of >500 U/ml. Three of the 32 (9.4%) patients with elevated KL-6 level >500 U/ml had idiopathic pulmonary fibrosis. Multivariate analysis showed that patients achieved elevated KL-6 when: (1) they had hepatocellular carcinoma (HCC; p = 0.0007), and (2) age was >60 years (p = 0.0085). The HCC rate was 37.5% (12/32) in the patients with elevated KL-6 and 8.3% (39/470) in the patients with normal KL-6 group. The median (range) age was 70 (56–77) years in the patients with elevated KL-6 group and 60 (12–92) years in the patients with normal KL-6. Conclusion: The patients with HCC aged >60 years had significantly elevated serum levels of KL-6.

show abstract

Section: Discussionsupporting

confidence: 94%

“…However, serum levels of KL-6 are sometimes elevated in patients with certain malignancies such as adenocarcinoma of the lung, breast, pancreas and HCC [28] . In the present study, the serum KL-6 level in patients with HCC was higher than that of patients without HCC by univariate analysis.…”

Section: Discussionmentioning

confidence: 99%

Usefulness of the Serum KL-6 Assay in Patients with Hepatitis C Virus

Arase

Ikeda²,

Suzuki³

et al. 2005

Intervirology

View full text Add to dashboard Cite

show abstract

“…However, serum levels of KL-6 are sometimes elevated in patients with certain malignancies such as adenocarcinoma of the lung, breast, pancreas and HCC (21,22). In the present study, none of the patients had malignancies for two years after the initiation of follow-up.…”

Section: Discussioncontrasting

confidence: 50%

Serum KL-6 Level is Elevated in Chronic Hepatitis C Patients with Combination Therapy of Pegylated Interferon and Ribavirin

et al. 2007

View full text Add to dashboard Cite

show abstract

“…To tackle the challenge, more prognostic biomarkers that could predict the progression and metastasis of cancer should be explored. Efforts have been made to find molecules of HCC progression and metastasis, including Alpha-fetoprotein (AFP) [20], Alpha-fetoprotein-L3 (AFPR-L3) [21], des-g-carboxy-prothrombin (DCP) [22], a-Fucosidase [23], Glypican-3 [24], transforming growth factor-b1 (TGFβ) [25], insulin-like growth factor-II (IGF-II) [26], insulin-like growth factor-binding protein-2 (IGFBP-2) [27], human cervical cancer oncogene (HCCR) [28], Golgi protein 73 (GP73) [29], hepatocyte growth factor (HGF) [30], KL-6 [31], vascular endothelial growth factor (VEGF) [32], and tumor-associated antigens (TAAs) [33]. However, HCC metastasis-associated indicators for clinical utility are still lacking.…”

Section: Discussionmentioning

confidence: 99%

Coronin-1C is a novel biomarker for hepatocellular carcinoma invasive progression identified by proteomics analysis and clinical validation

Peng

Hou

et al. 2010

J Exp Clin Cancer Res

View full text Add to dashboard Cite

BackgroundTo better search for potential markers for hepatocellular carcinoma (HCC) invasion and metastasis, proteomic approach was applied to identify potential metastasis biomarkers associated with HCC.MethodsMembrane proteins were extracted from MHCC97L and HCCLM9 cells, with a similar genetic background and remarkably different metastasis potential, and compared by SDS-PAGE and identified by ESI-MS/MS. The results were further validated by western blot analysis, immunohistochemistry (IHC) of tumor tissues from HCCLM9- and MHCC97L-nude mice, and clinical specimens.ResultsMembrane proteins were extracted from MHCC97L and HCCLM9 cell and compared by SDS-PAGE analyses. A total of 14 differentially expressed proteins were identified by ESI-MS/MS. Coronin-1C, a promising candidate, was found to be overexpressed in HCCLM9 cells as compared with MHCC97L cells, and validated by western blot and IHC from both nude mice tumor tissues and clinical specimens. Coronin-1C level showed an abrupt upsurge when pulmonary metastasis occurred. Increasing coronin-1C expression was found in liver cancer tissues of HCCLM9-nude mice with spontaneous pulmonary metastasis. IHC study on human HCC specimens revealed that more patients in the higher coronin-1C group had overt larger tumor and more advanced stage.ConclusionsCoronin-1C could be a candidate biomarker to predict HCC invasive behavior.

show abstract

Detection of serum and intrahepatic KL-6 in anti-HCV positive patients with hepatocellular carcinoma

Cited by 14 publications

References 27 publications

Usefulness of the Serum KL-6 Assay in Patients with Hepatitis C Virus

Usefulness of the Serum KL-6 Assay in Patients with Hepatitis C Virus

Serum KL-6 Level is Elevated in Chronic Hepatitis C Patients with Combination Therapy of Pegylated Interferon and Ribavirin

Coronin-1C is a novel biomarker for hepatocellular carcinoma invasive progression identified by proteomics analysis and clinical validation

Contact Info

Product

Resources

About